biosensis fine bioscience tools - antibodies, elisa kits, proteins, toxins and peptides An Australia-US partnershipPhone: 1800 605 5127 in the US, or +61 8 8352 7711 for international enquiries to Australia.
HomeAbout BiosensisBiosensis distributorsResourcesHelp deskordering from BiosensisContact us
 


Technical Notes
 
View our tech notes
 
 
Follow us...
 
Google+ Follow us on Twitter

Find us on Facebook

Sign up for Biosensis newsletters
Visit our newsletter archive
 
 
News and Site Information.

The Enigmatic p75NTR Neurotrophin Receptor


09/02/2014
New NGFR/p75ECD Rapid ELISA Kits only from Biosensis!

The Enigmatic p75NTR Neurotrophin Receptor

“They seek him here, they seek him there. Those Researchers seek him everywhere.... That damned elusive p75NTR!” (With apologies to Baroness Emmuska Orczy, The Scarlet Pimpernel).

p75NTR in pain signaling:

While NGF stimulation of TrkA is well known to trigger pain in sensory neurons (and antibodies to NGF are a potent treatment for many types of pain), Lewin and Nykjaer 2014 (PMID: 24494677) have critically reviewed the evidence for a pro-NT / p75NTR / sortilin complex, and proposed a possible role in both pain and sensory neuropathies.

p75NTR as a biomarker:

The first indication that p75NTR could function as a useful biomarker of disease or trauma was published 26 years ago by DiStefano and Johnson, 1988 (PMID: 2465632). A recent publication has progressed these early observations by showing a very strong correlation between p75NTR and disease progression in ALS (Amyotrophic Lateral Sclerosis) patients. Shepheard et al 2014 (PMID: 24475283). This bodes well for both early diagnosis and drug development potential for p75NTR.

p75NTR, beta Amyloid peptide and Alzheimer’s disease:

The intriguing finding that the neutotoxic effects of amyloid beta peptide are at least partially mediated by p75NTR is now understood to occur via a complex of the receptor with the Death Receptor-6 (DR6) protein Hu et al 2013 (PMID: 23559013). This finding provides yet another option for drug development in Alzheim- er’s disease.

NEW: NGFR/p75ECD Rapid™ ELISA kit: Human (Catalog # BEK-2219-2P)

Biosensis is proud to release a new NGFR/p75ECD Rapid™ ELISA kit for the quantification of human p75ECD in less than 4 hours. The purpose of this kit is the in vitro quantitative determination of mouse p75ECD in samples such as cell culture supernatants and urine.

Image: Standard curve of our new NGFR/p75ECD Rapid™ ELISA Kit: Human (Catalog # BEK-2219-2P).
This standard curve generated in our laboratories is for demonstration purposes only, but can be used as a guide to expected performance. A standard curve should be generated for each assay. 


NEW: NGFR/p75ECD Rapid™ ELISA kit: Mouse (Catalog # BEK-2220-2P)
Biosensis has recently released a new NGFR/p75ECD Rapid™ ELISA kit for the quantification of mouse p75ECD in less than 4 hours. The purpose of this kit is the in vitro quantitative determination of mouse p75ECD in samples such as cell culture supernatants and urine.

Image: Standard curve of our new NGFR/p75ECD Rapid™ ELISA Kit: Mouse (Catalog # BEK-2220-2P).
This standard curve generated in our laboratories is for demonstration purposes only, but can be used as a close guide to expected performance.





Please find more information of our new NGFR/p75ECD Rapid™ ELISA kits below:



Biosensis p75NTR and related products:

Mouse monoclonal antibody to human p75NTR [MLR2]: IgG2a
Mouse monoclonal antibody to human p75NTR [MLR2]: IgG2a] (Catalog # M-009-100). Image: Immunofluorescent staining of adult rat mesenteric nerves following in vivo intraperitoneal administration of labeled MLR2. This popular monoclonal is also available with a FITC label (Catalog # M-018-100-FT).



Mouse monoclonal antibody to rat p75NTR [MC192]: IgG

Image: Immunofluorescent detection of p75NTR [MC192] in cultured rat dorsal root ganglion (DRG) using Mouse monoclonal antibody to rat p75NTR [MC192] (Catalog # M-006-100). This popular monoclonal is also available with a FITC label (Catalog # M-016-100-FT).



Other related antibodies:


Continue